Hem › Endometriecancer › Virginia › Arlington
Kliniska studier för Endometriecancer i Arlington, VA
39 studier för Endometriecancer söker deltagare vid platser i och runt Arlington (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekryterarFas 2
- Inova Fairfax Hospital, Falls Church · 4 mi bort
- Inova Schar Cancer Institute, Fairfax · 11 mi bort
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RekryterarFas 1/2
- Research Site, Fairfax · 11 mi bort
A Study of PHST001 in Advanced Solid Tumors
RekryterarFas 1
- NEXT Oncology - Virginia, Fairfax · 11 mi bort
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekryterarFas 1
- Inova Schar Cancer Institute, Fairfax · 11 mi bort
- NEXT Virginia, Fairfax · 11 mi bort
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekryterarFas 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi bort
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekryterarFas 1
- NEXT Virginia, Fairfax · 11 mi bort
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
RekryterarFas 1
- Site 04, Fairfax · 11 mi bort
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekryterarFas 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · 11 mi bort
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekryterarFas 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi bort
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekryterarFas 1
- Virginia Cancer Specialists, Fairfax · 11 mi bort
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RekryterarFas 3
- Inova Schar Cancer Institute ( Site 6003), Fairfax · 11 mi bort
- Virginia Cancer Specialists (VCS) ( Site 8008), Fairfax · 11 mi bort
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RekryterarFas 1/2
- NEXT Oncology, Fairfax · 11 mi bort
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekryterarFas 1
- Virginia Cancer Specialists, Fairfax · 11 mi bort
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
RekryterarFas 1
- NEXT Oncology, Fairfax · 11 mi bort
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RekryterarFas 3
- Research Site, Fairfax · 11 mi bort
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
RekryterarFas 1
- NEXT Virginia, Fairfax · 11 mi bort
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RekryterarFas 1
- NEXT Virginia, Fairfax · 11 mi bort
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RekryterarFas 1
- Inova Schar Cancer Institute, Falls Church · 4 mi bort
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekryterarFas 1
- Normunity Investigational Site, Fairfax · 11 mi bort
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RekryterarFas 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi bort
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
RekryterarFas 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11 mi bort
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekryterarFas 1/2
- USOR Virginia Cancer Specialists, Fairfax · 11 mi bort
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RekryterarFas 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi bort
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RekryterarFas 3
- Research Site, Falls Church · 4 mi bort
- Research Site, Fairfax · 11 mi bort
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RekryterarFas 1
- NEXT Virginia, Fairfax · 11 mi bort
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
RekryterarFas 1
- NEXT Virginia, Fairfax · 11 mi bort
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RekryterarFas 2
- 522, Fairfax · 11 mi bort
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- USO-Virginia Cancer Specialists, PC, Fairfax · 11 mi bort
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
RekryterarFas 1
- NEXT Virginia, Fairfax · 11 mi bort
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekryterarFas 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi bort
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- NEXT, Fairfax · 11 mi bort
A Study of LY4175408 in Participants With Advanced Cancer
RekryterarFas 1
- NEXT Virginia, Fairfax · 11 mi bort
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RekryterarFas 1
- NEXT Texas LLC - Virginia, Fairfax · 11 mi bort
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RekryterarFas 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi bort
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
RekryterarFas 1
- Virginia Cancer Specialists, Fairfax · 11 mi bort
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
RekryterarFas 1
- Dren Investigational Site, Fairfax · 11 mi bort
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RekryterarFas 2
- Virginia Cancer Specialists, P.C., Fairfax · 11 mi bort
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RekryterarFas 1
- Virginia Cancer Specialists, Fairfax · 11 mi bort
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RekryterarFas 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi bort
Endometriecancer-studier i andra städer
- Houston, TX68 studier
- New York City, NY52 studier
- Boston, MA50 studier
- Nashville, TN38 studier
- Los Angeles, CA34 studier
- St. Louis, MO29 studier
- Philadelphia, PA28 studier
- San Antonio, TX27 studier
- Columbus, OH25 studier
- Oklahoma City, OK25 studier
- Chicago, IL25 studier
- Queens, NY25 studier
Andra studier i Arlington
- Icke-småcellig lungcancer104 studier
- Metastaserande cancer53 studier
- Kolorektal cancer52 studier
- Cancer (alla typer)48 studier
- Bröstcancer47 studier
- Äggstockscancer46 studier
- Lungcancer41 studier
- Bukspottkörtelcancer33 studier
- Plattenepitelcancer i huvud och hals26 studier
- Småcellig lungcancer23 studier
- Magsäckscancer20 studier
- Triplenegativ bröstcancer20 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.